Haematologica Reports 2005; 1(issue 12):
1-33[prev][index][next]
Nodal aggressive non-Hodgkin’s lymphoma in the
adult: a review article
Maurizio Martelli,1 Paolo Corradini,2 Antonio
Del Santo,3 Gianluca Gaidano,4 Alessandro
M.Gianni,5
Pellegrino Musto,6 Stefano Pileri,1
Alessandro Rambaldi,8 Pier Luigi Zinzani,9
Sante Tura9
1Dipartimento di Biotecnologie Cellulari ed Ematologia,
Università “La Sapienza” Roma;
2Divisione di Ematologia, Istituto Nazionale per lo
Studio e la Cura dei Tumori, Università di Milano;
3Direzione Medica Dompé Biotec, Milano;
4S.C.D.U. Ematologia, Dipartimento di Scienze Mediche
& IRCAD, Università del Piemonte Orientale Amedeo
Avogadro, Novara;
5Reparto “Cristina Gandini” Cattedra di
Oncologia Medica dell’Università degli Studi di Milano,
Istituto Nazionale dei Tumori;
6U.O di Ematologia e Trapianto di Cellule Staminali
IRCCS “Casa Sollievo della Sofferenza” San Giovanni
Rotondo;
7Cattedra di Anatomia Patologica, Servizio di
Ematopatologia, Istituto di Ematologia ed Oncologia Medica
“L. e A. Seragnoli, Università di Bologna;
8U.O di Ematologia, Programma di Trapianto di Midollo
Osseo, Ospedali riuniti di Bergamo;
9Istituto di Ematologia ed Oncologia Medica “L. e
A. Seragnoli, Università di Bologna, Italy
Background. The term aggressive lymphoma is a clinical
definition encompassing different lymphoid tumurs which are
potentially curable, but run a rapidly fatal course if not properly
treated. Under this definition, no longer quoted in the REAL/WHO
Classification, several histotypes are included that differ
remarkably in cell size and morphology, phenotypic and molecular
characteristics, kinetics and clinical presentation. Tailored
approaches have been designed aiming to adapt therapy to each
specific histotype.
Aim and design. Since aggressive lymphomas account for the majority
of lymphoid neoplasms, and because some variation exists as to
their categorization and treatment, the authors will discuss the
more recent and consolidated findings in the etiology,
pathogenesis, histopathology, diagnostics and therapy of such
tumours based on both the evidence in the literature and their own
expertise. In particular, each tumour type is individually
discussed, as are the most critical areas in patient
management.
Conclusions. An updated review of more recent biological and
therapeutic aspects is intended to assist the hematologist,
pathologist and practitioner in the optimal
management of patients with aggressive lymphoma.
Key words: aggressive non-Hodgkin lymphoma, chemotherapy,
chemoimmunotherapy, supportive therapy. [>Read
full article in PDF]
